Prostate cancer diagnosis in the new millennium: Strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3)

BJU International

Volumn 103, Issue 4, 2009, Pages 441-445

  Kirby, Roger S ^a   Fitzpatrick, John M ^b   Irani, Jacques ^c  

^a Prostate Centre   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Biopsy; Decision; PCA3; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; CANCER DIAGNOSIS; CANCER RISK; CASE REPORT; CLINICAL DECISION MAKING; CLINICAL EVALUATION; GENE IDENTIFICATION; HUMAN; INTERMETHOD COMPARISON; MALE; MARKER GENE; PATIENT CARE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROTEIN BLOOD LEVEL; REVIEW; TUMOR VOLUME;

ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 59249104985     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08280.x     Document Type: Review

References (25)

1. Schroder FH, van der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study for Prostate Cancer. J Natl Cancer Inst 1998 90 : 1817 23
2. Issa MM, Zasada W, Ward K et al. The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy. Cancer Detect Prev 2006 30 : 269 75
3. Richie JP, Catalona WJ, Ahmann FR et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993 42 : 365 74
4. Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Nat Cancer Inst 2006 98 : 529 34
5. Canby-Hagino E, Hernandez J, Brand TC et al. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/ml. Urology 2007 70 : 748 52
6. National Cancer Institute. Available at: http://www.cancer.gov/ cancertopics/factsheet/Detection/PSA. Accessed 25 July 2008
7. Nadler RB, Humphrey PA, Smith DS et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995 154 : 407 13
8. Sindhwani P, Wilson CM. Prostatitis and serum prostate-specific antigen. Curr Urol Rep 2005 6 : 307 12
9. Bhanot S, Gopalakrishnan R, Oliver RT. Post-biopsy rise in serum PSA. A potential tool for the dynamic evaluation of prostate cancer/prostatic intraepithelial neoplasia (PIN). Cancer Biol Ther 2003 2 : 67 70
10. Kiran PR. Markedly raised serum prostate specific antigen levels. Prostatic infarction rather than malignancy? Aust Fam Physician 2001 30 : 458 60
11. Oremek GM, Seiffert UB. Physical activity releases prostate-specific antigen (PSA) form the prostate gland into blood and increases serum PSA concentrations. Clin Chem 1996 42 : 691 5
12. Banez LL, Hamilton RJ, Partin AW et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007 298 : 2275 80
13. Fall K, Garmo H, Andren O et al. Prostate specific antigen level as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007 99 : 526 32
14. Zappa M, Ciatto S, Bonardi R et al. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 1998 9 : 1297 300
15. Bussemakers MJG, Van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specific gene, highly over-expressed in prostate cancer. Cancer Res 1999 59 : 5975 9
16. PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003 44 : 8 16
17. Haese A, de la Taille A, van Poppel H et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008 Epub ahead of print
18. Sokoll L, Ellis W, Lange P et al. A multicenter evaluation of the PCA3 molecular urine test: preanalytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 2008 389 : 1 6
19. Marks LS, Fradet Y, Deras IL et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007 69 : 532 5
20. van Gils MP, Hessels D, van Hooij O et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007 13 : 939 43
21. Deras IL, Aubin SMJ, Blase A et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008 179 : 1587 92
22. Groskopf J, Aubin SM, Deras IL et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006 52 : 1089 95
23. Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular urine assay correlates with prostate cancer tumour volume: implication in selecting candidates for active surveillance. J Urol 2008 179 : 1804 10
24. Parekh DJ, Ankerst DP, Groskopf J et al. Predicting prostate cancer risk through incorporation of a molecular biomarker, PCA3. AUA Annual Meeting, 2008
25. Welch GH, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States. Implications of various definitions for abnormal. JNCI 2005 97 : 1132 7